Influence of novel GPR119 agonist in combination with metformin and sitagliptin on glycemia, body weight and food intake in rats fed a high-fat diet
BACKGROUND: Metabolic syndrome and obesity are often precursors of type 2 diabetes mellitus (DM), and current recommendations indicate the advisability of early initiation of drug therapy at the stage of prediabetes. Drugs with incretin activity are one of the priority groups for monotherapy of type...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2019-12-01
|
| Series: | Ожирение и метаболизм |
| Subjects: | |
| Online Access: | https://www.omet-endojournals.ru/jour/article/view/9422 |
| _version_ | 1797204638072569856 |
|---|---|
| author | Ivan N. Tyurenkov Denis V. Kurkin Dmitry A. Bakulin Elena V. Volotova Ekaterina O. Logvinova Kseniia A. Avdienko Mihail A. Shafeev |
| author_facet | Ivan N. Tyurenkov Denis V. Kurkin Dmitry A. Bakulin Elena V. Volotova Ekaterina O. Logvinova Kseniia A. Avdienko Mihail A. Shafeev |
| author_sort | Ivan N. Tyurenkov |
| collection | DOAJ |
| description | BACKGROUND: Metabolic syndrome and obesity are often precursors of type 2 diabetes mellitus (DM), and current recommendations indicate the advisability of early initiation of drug therapy at the stage of prediabetes. Drugs with incretin activity are one of the priority groups for monotherapy of type 2 diabetes in the onset of the disease, and certain drugs are used to treat obesity. GPR119 agonists increase the secretion of endogenous incretins, and their effectiveness in the treatment of type 2 diabetes and obesity in mono- and combination therapy is currently being actively studied. AIM. To evaluate of the effect of administration of a GPR119 receptor agonist, its combination with metformin or sitagliptin on body weight, food intake and glycemia in rats under a high-calorie diet. MATERIALS AND METHODS: The study was conducted on 56 outbred female rats aged 7–8 months and an initial weight of 305–320 g. Compound ZB-16 is a highly active GPR119 receptor agonist (EC50 = 7 nM). For 12 weeks, the animals were kept on a high-fat and carbohydrate diet and at the same time received the compound ZB-16, metformin and sitagliptin, or its combination (ZB-16 + metformin and ZB-16 + sitagliptin). During the experiment, the weight of the animals, the mass of feed eaten, as well as the level of glycemia after 6 hours of fasting and with an oral glucose load were assessed. RESULTS: In animals of the control group that were on a high-calorie and fatty diet for 12 weeks, an increase in body weight, glycemia and a decrease in the rate of glucose utilization were observed. The introduction of the GPR119 agonist (ZB-16) for 12 weeks led to a significant reduction in the amount of food consumed, limited weight gain and prevented the development of carbohydrate metabolism disorders. The addition of sitagliptin and especially metformin to therapy with the GPR119 agonist significantly increased the effectiveness of therapy compared to the control group, which was expressed in the normalization of animal body weight and glycemia (p <0.05). CONCLUSIONS: The introduction of a combination of the GPR119 agonist (compound ZB-16) with metformin and sitagliptin is more effective than monotherapy in terms of weight gain, food intake, and also prevents the development of carbohydrate metabolism disorders in animals when kept on a high-fat and carbohydrate diet. |
| first_indexed | 2024-03-08T09:13:44Z |
| format | Article |
| id | doaj.art-e7f400c5efd1486195f2f496da05678c |
| institution | Directory Open Access Journal |
| issn | 2071-8713 2306-5524 |
| language | English |
| last_indexed | 2024-04-24T08:38:24Z |
| publishDate | 2019-12-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Ожирение и метаболизм |
| spelling | doaj.art-e7f400c5efd1486195f2f496da05678c2024-04-16T16:16:12ZengEndocrinology Research CentreОжирение и метаболизм2071-87132306-55242019-12-01163465410.14341/omet94228758Influence of novel GPR119 agonist in combination with metformin and sitagliptin on glycemia, body weight and food intake in rats fed a high-fat dietIvan N. Tyurenkov0Denis V. Kurkin1Dmitry A. Bakulin2Elena V. Volotova3Ekaterina O. Logvinova4Kseniia A. Avdienko5Mihail A. Shafeev6Volgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityChemical Diversity Research InstituteBACKGROUND: Metabolic syndrome and obesity are often precursors of type 2 diabetes mellitus (DM), and current recommendations indicate the advisability of early initiation of drug therapy at the stage of prediabetes. Drugs with incretin activity are one of the priority groups for monotherapy of type 2 diabetes in the onset of the disease, and certain drugs are used to treat obesity. GPR119 agonists increase the secretion of endogenous incretins, and their effectiveness in the treatment of type 2 diabetes and obesity in mono- and combination therapy is currently being actively studied. AIM. To evaluate of the effect of administration of a GPR119 receptor agonist, its combination with metformin or sitagliptin on body weight, food intake and glycemia in rats under a high-calorie diet. MATERIALS AND METHODS: The study was conducted on 56 outbred female rats aged 7–8 months and an initial weight of 305–320 g. Compound ZB-16 is a highly active GPR119 receptor agonist (EC50 = 7 nM). For 12 weeks, the animals were kept on a high-fat and carbohydrate diet and at the same time received the compound ZB-16, metformin and sitagliptin, or its combination (ZB-16 + metformin and ZB-16 + sitagliptin). During the experiment, the weight of the animals, the mass of feed eaten, as well as the level of glycemia after 6 hours of fasting and with an oral glucose load were assessed. RESULTS: In animals of the control group that were on a high-calorie and fatty diet for 12 weeks, an increase in body weight, glycemia and a decrease in the rate of glucose utilization were observed. The introduction of the GPR119 agonist (ZB-16) for 12 weeks led to a significant reduction in the amount of food consumed, limited weight gain and prevented the development of carbohydrate metabolism disorders. The addition of sitagliptin and especially metformin to therapy with the GPR119 agonist significantly increased the effectiveness of therapy compared to the control group, which was expressed in the normalization of animal body weight and glycemia (p <0.05). CONCLUSIONS: The introduction of a combination of the GPR119 agonist (compound ZB-16) with metformin and sitagliptin is more effective than monotherapy in terms of weight gain, food intake, and also prevents the development of carbohydrate metabolism disorders in animals when kept on a high-fat and carbohydrate diet.https://www.omet-endojournals.ru/jour/article/view/9422gpr119metforminsitagliptinobesityrats |
| spellingShingle | Ivan N. Tyurenkov Denis V. Kurkin Dmitry A. Bakulin Elena V. Volotova Ekaterina O. Logvinova Kseniia A. Avdienko Mihail A. Shafeev Influence of novel GPR119 agonist in combination with metformin and sitagliptin on glycemia, body weight and food intake in rats fed a high-fat diet Ожирение и метаболизм gpr119 metformin sitagliptin obesity rats |
| title | Influence of novel GPR119 agonist in combination with metformin and sitagliptin on glycemia, body weight and food intake in rats fed a high-fat diet |
| title_full | Influence of novel GPR119 agonist in combination with metformin and sitagliptin on glycemia, body weight and food intake in rats fed a high-fat diet |
| title_fullStr | Influence of novel GPR119 agonist in combination with metformin and sitagliptin on glycemia, body weight and food intake in rats fed a high-fat diet |
| title_full_unstemmed | Influence of novel GPR119 agonist in combination with metformin and sitagliptin on glycemia, body weight and food intake in rats fed a high-fat diet |
| title_short | Influence of novel GPR119 agonist in combination with metformin and sitagliptin on glycemia, body weight and food intake in rats fed a high-fat diet |
| title_sort | influence of novel gpr119 agonist in combination with metformin and sitagliptin on glycemia body weight and food intake in rats fed a high fat diet |
| topic | gpr119 metformin sitagliptin obesity rats |
| url | https://www.omet-endojournals.ru/jour/article/view/9422 |
| work_keys_str_mv | AT ivanntyurenkov influenceofnovelgpr119agonistincombinationwithmetforminandsitagliptinonglycemiabodyweightandfoodintakeinratsfedahighfatdiet AT denisvkurkin influenceofnovelgpr119agonistincombinationwithmetforminandsitagliptinonglycemiabodyweightandfoodintakeinratsfedahighfatdiet AT dmitryabakulin influenceofnovelgpr119agonistincombinationwithmetforminandsitagliptinonglycemiabodyweightandfoodintakeinratsfedahighfatdiet AT elenavvolotova influenceofnovelgpr119agonistincombinationwithmetforminandsitagliptinonglycemiabodyweightandfoodintakeinratsfedahighfatdiet AT ekaterinaologvinova influenceofnovelgpr119agonistincombinationwithmetforminandsitagliptinonglycemiabodyweightandfoodintakeinratsfedahighfatdiet AT kseniiaaavdienko influenceofnovelgpr119agonistincombinationwithmetforminandsitagliptinonglycemiabodyweightandfoodintakeinratsfedahighfatdiet AT mihailashafeev influenceofnovelgpr119agonistincombinationwithmetforminandsitagliptinonglycemiabodyweightandfoodintakeinratsfedahighfatdiet |